Gain Client Recognition Again! Medicilon won the 2023 SicaGene "Best Partner Award"

Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene. The strong support provided in collaboration projects has been recognized by client again.

Medicilon and SicaGene: Go Deep Alone, Go Far Together

The collaboration stems from a shared vision in the field of nucleic acid drugs. Antisense oligonucleotide drugs can break through the "undruggable targets" limitations of traditional small molecule drugs, but they also have extremely high technical barriers and development difficulties. As one of the first China innovative pharmaceutical companies to enter the ASO field, SicaGene has independently developed and constructed core technology platforms such as SicaScreenTM、SicaChemistryTM、SicaDeliveryTM , focusing on drug development in the fields of cardiovascular disease, viruses, and ophthalmology. SicaGene has also achieved efficient development of ASO drugs with high activity, low dosage, long administration cycle, good clinical tolerance and controllable cost.

It is also Medicilon's vision to improve the druggability and R&D efficiency of nucleic acid drugs and help nucleic acid drugs benefit the world. To this end, Medicilon relies on the Nucleic Acid Drug R&D Service Platform to empower SicaGene's ASO drug research and development, and the trust and support from SicaGene also encourage Medicilon to continue to innovate and improve. Through close collaboration between the two parties, the collaboration has achieved positive progress and phased results.

Nucleic Acid Drug R&D Service Platform provides one-stop support for R&D

Medicilon's Nucleic Acid Drug R&D Service Platform is an integrated and comprehensive platform that integrates drug discovery, production and preclinical research. Based on a rigorous scientific attitude, an open technology platform and advanced instruments and equipment, Medicilon can provide nucleic acid drug discovery, screening and preclinical research services to pharmaceutical companies and scientific research institutions.

Medicilon will continue to target cutting-edge tracks such as nucleic acid, cell and gene therapy, PROTAC, and ADC, strengthen technological innovation, and gather superior resources to provide clients with a one-stop biopharmaceutical preclinical R&D service platform and to empower global partners to accelerate pharmaceutical innovation.

此博客中的热门博文

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Shanghai Medicilon Inc.

搜索此博客